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ABSTRACT
Cancer cells initially characterized as sensitive to chemotherapy may acquire 
resistance to chemotherapy and lead to tumor recurrence through the expansion of 
drug-resistant population. Acquisition of drug resistance to conventional chemotherapy 
is a major obstacle in the treatment of recurrent cancer. Here we investigated whether 
anticancer drugs induced Oct4 expression, thereby contributing to acquired drug 
resistance and tumor recurrence in bladder cancer. We identified a positive correlation 
of Oct4 expression with tumor recurrence in 122 clinical specimens of superficial 
high-grade (stages T1-2) bladder transitional cell carcinoma (TCC). Increased Oct4 
levels in bladder tumors were associated with short recurrence-free intervals in the 
patients. Chemotherapy induced Oct4 expression in bladder cancer cells. Notably, 
treatment with cisplatin increased CD44-positive bladder cancer cells expressing 
Oct4, representing cancer stem-like cell subpopulation. Forced expression of Oct4 
reduced, whereas knockdown of Oct4 enhanced, drug sensitivity in bladder cancer 
cells. Furthermore, tumor cells overexpressing Oct4 responded poorly to cisplatin in 
vivo. In regard to clinical relevance, inhibition of Oct4 by all-trans retinoic acid (ATRA) 
synergistically increased sensitivity to cisplatin in bladder cancer cells. Furthermore, 
the combination of cisplatin and ATRA was superior to cisplatin alone in suppressing 
tumor growth. Therefore, our results provide evidence that Oct4 increases drug 
resistance and implicate that inhibition of Oct4 may be a therapeutic strategy to 
circumvent drug resistance.
INTRODUCTION
Cancer cells that have been initially characterized 
as sensitive to chemotherapy may acquire resistance 
to chemotherapy and lead to tumor recurrence through 
the expansion of drug-resistant population. Platinum-
based drugs such as cisplatin are the standard first-line 
agents used alone or in combination with other drugs 
for cancer treatment. However, tumors can recur and 
develop chemoresistance [1]. Solid tumors possess a 
rare population of cancer stem cells (CSCs), which have 
similar characteristics to normal stem cells and exhibit 
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self-renewal, asymmetric cell division, and resistance to 
toxic agents [2]. CSCs display surface markers, including 
CD44 and CD133, in various cancer types [3]. CD44 and 
CD133 have been identified as surface biomarkers for 
cancer cells resistant to chemotherapeutic drugs [4–6]. 
CSC-like cells are enriched following short-term single 
treatment of chemotherapy, suggesting that malignant cells 
may also be enriched by cisplatin treatment [6].
Oct4, a member of POU homeobox gene family, is 
a transcription factor capable of binding to an octameric 
consensus sequence to activate its target genes [7]. It 
functions in maintaining pluripotency and self-renewal of 
embryonic stem (ES) cells [8]. Oct4 is highly expressed 
in lung cancer-derived CD133- and CD44-positive cells, 
anticancer drug-selected breast cancer cells, and side 
population (SP) cells from bladder and ovarian cancer 
cells with characteristics of CSCs [9–13], which exhibit 
enhanced resistance to chemotherapeutic agents, such as 
cisplatin. We have previously shown that Oct4 is detected 
and predicts tumor progression and metastasis in bladder 
cancer [14]. Moreover, we have also demonstrated that 
Oct4-regulated oncolytic adenovirus can kill CD44- and 
CD133-positive bladder cancer cells [15]. Expression of 
Oct4 in CSC-like cell population not only promotes cell 
growth, but also resists chemotherapy [16], suggesting a 
role for Oct4 in regulating drug resistance.
Bladder carcinoma is the most common urothelial 
malignancy in more developed countries [17]. Transitional 
cell carcinoma (TCC) is the most common bladder 
tumor and ~90% of bladder TCC are superficial at initial 
diagnosis. Although primary tumors can be eliminated by 
surgery, chemotherapy, or radiotherapy, the tumors recur 
frequently and may progress to muscle-invasive disease 
[18]. The acquisition of drug resistance in recurrent tumors 
is a critical factor that limits successful cancer treatment. 
Resistance to common chemotherapeutic agents involves 
multiple mechanisms, which can be intrinsic or acquired 
during treatment [19]. Since acquired drug resistance is an 
important contributor to the recurrence and progression 
of bladder cancer, elucidating its underlying mechanisms 
may provide novel therapeutic strategies for bladder 
cancer.
In the present study, we investigated whether 
anticancer drugs induced Oct4 expression, thereby 
contributing to acquired drug resistance and tumor 
recurrence in bladder cancer. Our results show that 
expression of Oct4 was positively correlated with tumor 
recurrence in clinical specimens of bladder cancer. Our in 
vitro and in vivo studies also demonstrate that induction 
of Oct4 expression after treatment with anticancer 
drugs rendered bladder cancer cells chemoresistant. In 
conclusion, our results provide evidence that Oct4 can 
induce drug-acquired chemoresistance in bladder cancer, 
and implicate that inhibition of Oct4 may be further 
explored as a therapeutic strategy to counteract acquired 
drug resistance.
RESULTS
Expression levels of Oct4 are increased in 
recurrent bladder cancer and positively 
correlated with tumor recurrence
As expression of Oct4 is associated with tumor 
progression and chemotherapy resistance, we first 
examined the expression levels of Oct4 in 122 clinical 
specimens of superficial high-grade (stages T1-2) bladder 
TCC of 110 patients, among which 24 specimens were 
paired primary and recurrent samples from 12 patients. 
Figure 1A shows that the immunoreactive intensity for 
Oct4 was individually scored as 0-3 and categorized as 
low (0-1), moderate (2), or high (3) [14, 20]. Kaplan-Meier 
analysis reveals that patients with Oct4 high-expressing 
tumors (score 3) had significantly shorter recurrence-free 
intervals (median = 13 months) than those with Oct4 low-
expressing tumors (score 0-2) (median = 34.5 months) (P
< 0.001) (Figure 1B). We further analyzed the expression 
levels of Oct4 in 12 paired primary and recurrent tumor 
specimens. Expression levels of Oct4 in recurrent 
tumors were higher than those in their primary tumor 
counterparts (Figure 1C). As shown in Figure 1D, much 
higher percentages of tumors with high expression (score 
3) of Oct4 and much lower percentages of tumors with 
low expression (score 0-1) of Oct4 were noted in recurrent 
tumors than in primary tumors (P < 0.001). We also used 
quantitative real-time reverse transcription-polymerase 
chain reaction (RT-PCR) analysis to assess Oct4 
expression in bladder tumor and normal tissue. Figure 1E 
show that mRNA levels of Oct4 were significantly higher 
in bladder tumor than in normal tissue. Taken together, we 
identified a positive correlation of Oct4 expression with 
bladder tumor recurrence.
Expression of Oct4 is increased in bladder 
cancer cells following chemotherapeutic 
treatment
We investigated whether Oct4 was involved in 
acquired resistance induced by anticancer drugs. As shown 
in 2A, protein levels of Oct4 were dramatically increased 
in TCCSUP, J82, and TSGH-8301 bladder cancer cells 
after treatment with 1 μg/ml of cisplatin for 24 h. Figure 
2B shows that TCCSUP cells expressed Oct4 upon 
cisplatin treatment in a dose-dependent manner. Bladder 
cancer cells, including TCCSUP, J82, and T24 cells, 
expressed higher levels of Oct4 mRNA than SV-HUC-1 
normal human urothelial cells, as determined by real-time 
quantitative RT-PCR analysis (Figure 2C). The mRNA 
levels of Oct4 were increased in TCCSUP cells treated 
with cisplatin, 5-fluorouracil (5-FU), and doxorubicin, 
whereas treatment with mitomycin C or paclitaxel (Taxol) 
had no such effects (Figure 2D). Furthermore, Oct4 
protein induced by cisplatin in different bladder cancer 
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Figure 1: High levels of Oct4 expression are correlated with tumor recurrence in patients with high-grade superficial 
bladder TCC. A. Immunohistochemical detection of Oct4 expression in three representative tumor sections (scores 0-1, 2, and 3). The 
immunoreactivity was scored on the basis of the percentage of positive cells (positive staining in <30% (scores 0-1), 30%-70% (score 2), 
and >70% (score 3) of cells). Negative control slides stained with isotype control mouse IgG were included. B. Kaplan-Meier curves of 
recurrence-free rate in 110 patients with high (score 3) or low (score 0-2) Oct4 expression. Differences in recurrence-free intervals were 
analyzed by the log-rank test. C. Representative immunohistochemical staining of Oct4 in paired primary and recurrent tumor specimens. 
Negative control slides stained with isotype control mouse IgG were included. D. Percentages of primary (n = 12) and recurrent (n = 12) 
tumors that expressed Oct4 with different scores (P < 0.001, Mann-Whitney U test). E. Relative mRNA levels of Oct4 in human bladder 
tumor and normal tissue determined by real-time RT-PCR analysis. Values shown are the mean ± SEM (n = 3). Results are representatives 
of two independent experiments.
Oncotarget4www.impactjournals.com/oncotarget
Figure 2: Treatment with cisplatin increases Oct4 expression in bladder cancer cells. A, B. Detection of Oct4 in TCCSUP, 
J82, and TSGH-8301 cells treated with cisplatin (1 μg/ml) (A) and in TCCSUP cells treated with various concentrations of cisplatin (B) 
for 24 h by immunoblotting. Expression of β-actin serves as the loading control. Ratios between the intensity of the bands corresponding 
to Oct4 and those corresponding to β-actin, which were quantitated by densitometry, were calculated. C, D. Detection of mRNA levels of 
Oct4 in bladder cancer cells (TCCSUP, J82, and T24 cells) and immortalized uroepithelial SV-HUC-1 cells (C) and in TCCSUP cells after 
treatment with various chemotherapeutic drugs at IC50 concentrations for 72 h (D) by quantitative real-time RT-PCR analysis. Values shown 
are the mean ± SEM (n = 3). Results are representatives of two independent experiments. E. Detection of Oct4 in TCCSUP, J82, and T24 
cells following cisplatin treatment by double immunofluorescence staining. The cells were treated with cisplatin (1 μg/ml) or left untreated 
for 48 h. They were stained with mouse anti-Oct4 monoclonal antibody, and subsequently stained with Alexa Fluor488-goat anti-mouse 
IgG. The nucleus was counterstained with DAPI. Expression and localization of Oct4 were observed under fluorescence microscopy at a 
magnification of ×400. Scale bar, 50 μm.
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cells was located in the nucleus (Figure 2E). Collectively, 
these results suggest that expression of Oct4 was enhanced 
in bladder cancer cells that had been exposed to various 
anticancer drugs.
CD44-positive cells expressing Oct4 are 
increased in bladder cancer cells following 
cisplatin treatment
Since Oct4 is considered a key maintainer of CSC 
pluripotency, we next explored whether expression of Oct4 
and CD44 was increased in bladder cancer cells following 
cisplatin treatment. Immunofluorescence analysis show 
that treatment with cisplatin enhanced the expression of 
both CD44 and Oct4 in bladder cancer cells (Figure 3A), 
Notably, CD44 was colocalized with Oct4, suggesting 
concurrent upregulation of CD44 and Oct4 during cisplatin 
treatment. Moreover, we compared the tumor growth of 
NOD/SCID mice inoculated with parental TCCSUP cells 
and that inoculated with cisplatin-resistant TCCSUP cells 
following 5 doses of cisplatin treatment every other day 
from day 5 after tumor cell inoculation. Figure 3B shows 
that cisplatin-resistant TCCSUP tumors grew faster and 
larger than the parental tumors (P < 0.001), indicating that 
drug-resistant tumors progressed more rapidly than did 
parental tumors, which may be attributed to the elevation 
of Oct4 after chemotherapy. Expression of Oct4 in the 
CD44-positive tumor cells could also be detected, albeit 
in a small percentage, in the tissue slices of cisplatin-
resistant TCCSUP tumor xenografts after cisplatin 
treatment (Figure 3C), suggesting a potential role for 
Oct4 in the poor response of tumors to cisplatin treatment. 
Colocalization between Oct4 and CD44 expression was 
also observed in the clinical tumor specimens from two 
patients with bladder cancer (Figure 3D). Taken together, 
these results suggest that CD44-positive cancer cells 
expressing Oct4 are induced by cisplatin, which may 
contribute to drug resistance.
Overexpression of Oct4 in bladder cancer 
confers resistance to cisplatin in vitro and in vivo
We next investigated whether Oct4 contributed to 
cisplatin-induced acquired drug resistance. We generated 
Oct4-overexpressing and vector control TCCSUP cells 
using lentivirus-mediated gene transfer (Figure 4A). 
Overexpression of Oct4 resulted in a five-fold increase 
in the 50% inhibitory concentration (IC50) value of 
cisplatin in Oct4-overexpressing TCCSUP cells (3.43 
± 0.2 μM) compared to their control counterparts (0.67 
± 0.086 μM) (P < 0.0001) (Figure 4B). To verify the 
contribution of Oct4 to drug resistance in vivo, we treated 
NOD/SCID mice bearing human TCCSUP-vector or 
TCCSUP-Oct4 xenografts with cisplatin or saline. As 
shown in Figure 4C, mice bearing TCCSUP-Oct4 tumors 
had larger tumor volumes than those bearing TCCSUP-
vector tumors without cisplatin treatment (P = 0.0002). 
Whereas treatment with cisplatin significantly retarded 
tumor growth in mice bearing TCCSUP-vector tumors 
(P < 0.0001), it had no effects on reducing tumor growth 
in mice bearing TCCSUP-Oct4 tumors compared to 
treatment with saline. These results indicate that Oct4-
overexpressing tumors responded poorly to cisplatin 
treatment. At day 44 after tumor cell inoculation, 
tumors were resected from the tumor-bearing mice for 
immunohistochemical examination. As shown in Figure 
4D, TCCSUP-vector tumors, in particular TCCSUP-
Oct4 tumors, expressed higher levels of Oct4 following 
cisplatin treatment compared with those without treatment. 
Collectively, overexpression of Oct4 in cisplatin-treated 
mice suggests that the mechanism underlying acquired 
drug resistance may involve Oct overexpression.
Knockdown of Oct4 expression enhances 
sensitivity of bladder cancer cells to various 
chemotherapeutic agents
To further verify the correlation of Oct4 expression 
with drug resistance in bladder cancer cells, we generated 
lentivirus-mediated stable Oct4-knockdown cells and 
their control cells. In the Oct4-knockdown TCCSUP, 
expression of Oct4 transcripts was suppressed to various 
degrees in two different knockdown cells (Supplementary 
Figure S1). Susceptibilities of Oct4-knockdown cells to 
various chemotherapeutic agents were examined. Table 1 
shows that except for mitomycin C, knockdown of Oct4 
expression rendered TCCSUP cells more susceptible to the 
chemotherapeutic agents tested, including cisplatin, 5-FU, 
doxorubicin, paclitaxel, gemcitabine, and methotrexate. 
Taken together, these results demonstrate that suppression 
of Oct4 expression in bladder cancer cells results in 
increased sensitivity to various chemotherapeutic agents.
All-trans retinoic acid (ATRA) synergistically 
enhances cisplatin-induced cytotoxicity in 
bladder cancer cells
ATRA, a powerful differentiating agent, can 
suppress Oct4 gene expression because it can influence 
multiple signaling pathways involved in stem cell 
maintenance [21]. ATRA is transported into the nucleus 
by binding to retinoid acid receptor α (RARα). Expression 
of RARα was detected in TCCSUP, TSGH-8301, 
and J82 cells, and no significant changes were found 
after treatment with cisplatin (Figure 5A). We further 
investigated the effect of ATRA on the expression of Oct4 
and RARα in cisplatin-treated TCCSUP and J82 cells. As 
shown in Figure 5B, treatment with ATRA significantly 
decreased the expression of Oct4 and RARα in TCCSUP 
cells in the presence of cisplatin. However, such effects 
were not evident in J82 cells. To further determine whether 
treatment with ATRA in bladder cancer cells could 
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Figure 3: Treatment with cisplatin increases CD44-positive cells expressing Oct4 in bladder cancer. A. Detection of 
CD44 and its colocalization with Oct4 in TCCSUP and J82 cells by double immunofluorescence staining. Cells were treated with cisplatin 
(1 μg/ml) or left untreated for 24 h. They were stained with PE-conjugated mouse anti-CD44 monoclonal antibody and mouse anti-Oct4 
monoclonal antibodies, and subsequently stained with Alexa Fluor488-goat anti-mouse IgG. Expression and colocalization of CD44 and 
Oct4 were observed under fluorescence microscopy at a magnification of ×200. Scale bar, 100 μm. The merged column represents the 
superposition of the cells stained with anti-CD44 and anti-Oct4. B. Tumor volumes in mice bearing parental or cisplatin-resistant TCCSUP 
tumors after cisplatin treatment. NOD/SCID mice were inoculated subcutaneously with parental TCCSUP or cisplatin-resistant TCCSUP 
(CR-TCCSUP) cells (1 × 107) at day 0, followed by intraperitoneal injection of cisplatin (4 mg/kg) at days 5, 7, 9, 11 and 13. Values shown 
are the mean ± SEM (n = 5). C, D. Detection of CD44 and its colocalization with Oct4 in human bladder tumor xenografts obtained from 
the tumor-bearing mice (C) and in human bladder tumor tissue of cancer patients (D). Tumors were excised at day 50 from the mice that 
had been inoculated with CR-TCCSUP cells and treated with cisplatin as described in B. Human tumor specimens were obtained from 
two bladder cancer patients. Double immunofluorescence staining was performed as described in A. The nucleus was counterstained with 
DAPI. Scale bar, 100 μm.
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Figure 4: Overexpression of Oct4 confers resistance to cisplatin in bladder cancer. A. Detection of Oct4 in TCCSUP cells 
that had been transduced with lentiviral vectors expressing Oct4 or with control lentiviral vectors by immunoblotting. Expression of β-actin 
serves as the loading control. Ratios between the intensity of the bands corresponding to Oct4 and those corresponding to β-actin, which 
were quantitated by densitometry, were calculated. B. A five-fold increase in the IC50 value of cisplatin in Oct4-overexpressing cancer cells. 
Oct4-overexpressing TCCSUP or control cells were treated with various concentrations of cisplatin for 72 h. Cell viability was assessed 
by the WST-8 assay to determine the IC50 value. Values represent the relative cell survival, with the viability in the control cells without 
cisplatin treatment arbitrarily set to 100. Values shown are the mean ± SEM (n = 4). C. Tumor volumes in mice bearing Oct4-overexpressing 
or control TCCSUP tumors treated with cisplatin or saline. NOD/SCID mice were inoculated subcutaneously with Oct4-overexpressing or 
control TCCSUP cells (2 × 106) at day 0, followed by intraperitoneal injection of cisplatin (4 mg/kg) or saline when tumor volumes reached 
100 mm3. Values shown are the mean ± SEM (n = 5-8). D. Immunohistochemical staining for Oct4 in the tumors excised at day 45 from the 
mice described in C (×400 magnification, scale bar, 50 μm). Negative control slides stained with isotype control mouse IgG were included.
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increase their sensitivity to cisplatin, we combined ATRA 
with cisplatin to treat bladder cancer cells. The IC50 value 
of cisplatin in TCCSUP cells was significantly lower in 
ATRA-treated cells than in the vehicle (solvent)-treated 
control cells (mean ± SEM, 1.31 ± 0.19 versus 1.91 ± 
0.27 μM; P = 0.0319) (Figure 5C). We next evaluated 
the combination effect of cisplatin and ATRA on the 
cytotoxicity of TCCSUP cells using the coefficient of 
drug interaction (CDI) [22–24]. The value of the CDI for 
the combination of cisplatin (ranging from 0.5 to 10 μg/
ml) with ATRA (0.1 μM) was less than 1, indicative of a 
synergistic effect (Figure 5D).
Combination treatment of cisplatin with ATRA 
inhibits the growth of bladder tumor
We next evaluated the effects of cisplatin and ATRA 
alone or in combination on the growth of bladder tumor 
in vivo. We treated TCCSUP tumor-bearing mice with 
ATRA, cisplatin, the vehicle (solvent), or saline alone 
and monitored their tumor growth. Single treatment 
with either cisplatin or ATRA significantly slowed tumor 
growth compared to their control counterparts, with 
cisplatin being more effective than ATRA (Figure 6A). 
Nevertheless, mice treated with cisplatin expressed higher 
levels of Oct4 compared with the remaining three groups 
of mice (Figure 6B). As shown in Figure 6C, although 
treatment with cisplatin plus solvent significantly retarded 
tumor growth compared with saline treatment in TCCSUP 
tumor-bearing mice (P = 0.0066), combination treatment 
with cisplatin and ATRA was superior to single treatment 
with cisplatin (P = 0.0047). Compared with saline-treated 
group, higher levels of Oct4 in the tumors were detected in 
mice receiving cisplatin alone or in combination with the 
vehicle (solvent) (Figure 6D). By contrast, combination 
treatment with cisplatin and ATRA abrogated cisplatin-
induced Oct4 expression. Therefore, these results suggest 
that induction of Oct4 may be involved in the acquired 
drug resistance induced by cisplatin. Furthermore, 
ATRA, which inhibits Oct4 expression, may provide 
potential therapeutic benefits toward the effectiveness of 
chemotherapeutic agents for cancer therapy.
DISCUSSION
Early detection of cancer has been improved in 
recent years; however, the prognosis of patients with 
some cancers especially those with late stage remains 
poor, mostly due to development of drug resistance, 
followed by tumor recurrence. In the present study, we 
analyzed 122 clinical specimens of superficial high-
grade bladder TCC of 110 patients for Oct4 expression 
by immunohistochemistry. Patients with high expression 
levels of Oct4 were associated with short recurrence-
free intervals. Expression levels of Oct4 in recurrent 
tumors were significantly higher than those in primary 
tumors. We further investigated a potential role for 
Oct4 in drug resistance of bladder cancer in vitro and 
in mice. Treatment with various chemotherapeutic 
drugs increased Oct4 expression in bladder cancer cells. 
Moreover, overexpression of Oct4 reduced, whereas 
knockdown of Oct4 enhanced, sensitivity to anticancer 
drugs. Collectively, our results indicate that Oct4 
increases the resistance of bladder cancer against various 
Table 1: IC50 values of various chemotherapeutic agents in Oct4-knockdown and control TCCSUP cells
Drug shLuc shOct4  
TRCN4882 TRCN4883  
IC50 IC50 P IC50 P Unit
Cisplatin 0.85 ± 0.12 0.44 ± 0.09 *** 0.70 ± 0.21 * μM
5-FU 0.97 ± 0.27 0.38 ± 0.01 *** 0.46 ± 0.09 ** μM
Doxorubicin 11.9 ± 2.59 6.21 ± 0.86 *** 10.17 ± 2.41 *** nM
Mitomycin C 93.02 ± 11.96 93.32 ± 19.44 N.S. 86.14 ± 17.95 N.S. nM
Paclitaxel 5.74 ± 0.47 2.69 ± 0.23 *** 3.51 ± 0.35 *** nM
Gemcitabine 37.71 ± 1.00 6.01 ± 1.00 *** 11.35 ± 0.67 *** nM
Methotrexate 17.38 ± 1.32 8.58 ± 0.44 *** 13.64 ± 0.66 *** nM
TCCSUP cells (2 × 103) that had been transduced with lentiviral vectors expressing shOct4 or shLuc were seeded in 
96-well plates overnight and refed with fresh medium containing different concentrations of chemotherapeutic agents. 
After 72 h, cell viability was assessed with the WST-8 assay to determine IC50 values. Values shown are the mean ± SD 
from three independent experiments. Statistical differences in the IC50 value between shOct4 and shLuc knockdown cells 
were analyzed by two-way ANOVA with Bonferroni post hoc test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; N.S., non-
significant.
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chemotherapeutic agents. However, the exact role of 
Oct4 overexpression in drug resistance and its underlying 
molecular mechanism have yet to be elucidated.
The unique capabilities of proliferation, 
tumorigenesis, and chemoresistance of CSCs make 
these cells an attractive therapeutic target and an ideal 
candidate for developing strategies aiming at preventing 
cancer recurrence. CD44 and CD133 are the most 
common CSC markers and broadly expressed on cancer 
cells [25–28]. Although there are various CSC markers, 
such as CD133, CD44, and ALDH1, displayed on cancer 
cells, Oct4 expression in these cells plays a major role 
in anti-apoptosis and maintenance of pluripotency. In 
the present study, we show that CD44-positive cells that 
expressed Oct4 were dramatically increased in bladder 
cancer cell lines after cisplatin treatment. Moreover, 
colocalization of CD44 with Oct4 was detectable, albeit 
in a small percentage of cells, in human bladder tumor 
xenografts that were resistant to cisplatin treatment. Our 
results suggest that bladder cancer cells undergo CSC-like 
changes after exposure to cisplatin. Genetic instability 
or environmental stimulation may result in genetic or 
epigenetic changes, revealing the flexibility of cancer cells. 
The chemotherapy-induced stemness phenotype of cancers 
is acquired and maintained by Oct4 [29]. During cisplatin 
treatment, activation of the Oct4 gene was attributed to 
decreased promoter methylation [16]. Oct4 can enhance 
survivin expression to promote cancer cell proliferation 
[30] and is critical for survival/anti-apoptosis of murine 
ES cells [31]. Our results show that the induction of 
Oct4 enhances the acquisition of CSC phenotypes and 
resistance to cisplatin in bladder cancer cells. In addition 
to cisplatin, treatment of lung cancer cells with 5-FU, 
doxorubicin, etoposide, and methotrexate has been shown 
to enrich CSC-like cells with drug resistance [32].
Transcription factors are involved in the regulation 
of stress-inducible genes. Oct1, which belongs to the same 
POU homeobox gene family as Oct4, is induced after 
Figure 5: Combination treatment with cisplatin and ATRA increases sensitivity to cisplatin in bladder cancer cells.
A, B. Detection of RARα in TCCSUP, TSGH-8301, and J82 cells treated with or without cisplatin (1 μg/ml) for 24 h (A), and Oct4 and 
RARα in TCCSUP and J82 cells treated with cisplatin (1 μg/ml) in the presence of ATRA (2.5 μM) or the vehicle (solvent) for 24 h (B) by 
immunoblotting. Expression of β-actin serves as the loading control. Ratios between the intensity of the bands of the indicted proteins and 
those corresponding to β-actin, which were quantitated by densitometry, were calculated. C. Cell viability after treatment with cisplatin 
alone or combined with ATRA. TCCSUP cells were treated with various concentrations of cisplatin plus ATRA (2.5 μM), saline, or the 
vehicle (solvent). After 72 h, cell viability was determined with the WST-8 assay to determine the IC50 values. D. Synergistic effect of 
cisplatin plus ATRA. TCCSUP cells were treated as described in C, except that 0.1 μM of ATRA was used. The values of the CDI for the 
combination treatment of indicated concentrations of cisplatin plus ATRA were calculated.
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cells are exposed to different DNA-damaging agents, 
such as cisplatin [33]. Furthermore, different transcription 
factors have been shown to play roles in the acquisition of 
cellular resistance to cisplatin, such as NF-κB, YB-1, and 
activating transcription factor 4 [34]. In the current study, 
we demonstrate that treatment with cisplatin, 5-FU, and 
doxorubicin, but not mitomycin C and paclitaxel, induces 
Oct4 expression. Moreover, knockdown of endogenous 
Oct4 expression sensitizes bladder cancer cells to 
cisplatin, 5-FU, doxorubicin, paclitaxel, gemcitabine, and 
methotrexate, but not to mitomycin C. Despite the fact 
that Oct4 is not induced following paclitaxel treatment, 
knockdown of Oct4 enhances sensitivity of bladder 
cancer cells to paclitaxel. Notably, mitomycin C fails 
to induce Oct4 expression. Furthermore, knockdown of 
Oct4 expression in bladder cancer cells does not affect 
their sensitivity to mitomycin C. Taken together, these 
results suggest that Oct4 either directly or indirectly 
contributes to the cross-resistance of bladder cancer cells 
to the chemotherapeutic drugs used for patients with 
bladder cancer, including cisplatin, 5-FU, doxorubicin, 
paclitaxel, gemcitabine, and methotrexate. However, 
resistance mechanism of mitomycin C in bladder cancer 
is independent of Oct4. Given multiples functions of Oct4 
in cancer cells, further studies are required to elucidate the 
mechanisms underlying the role of Oct4 in the resistance 
of bladder cancer cells to different anticancer drugs.
Patients with metastatic bladder cancer are treated 
with cisplatin-containing systemic chemotherapy, such 
as gemcitabine plus cisplatin, as the standard first-line 
therapy. However, treatment failure is commonly caused 
by the development of drug resistance. Resistance 
mechanisms to cisplatin in cancer cells include reduced 
cellular uptake, increased efflux, increased DNA repair, 
and hypermethylation of the MLH1 gene, a mismatch 
repair gene [19]. In the present study, we demonstrate 
that treatment with cisplatin increases expression of Oct4, 
contributing to chemoresistance and tumor recurrence. 
Figure 6: Combination treatment with cisplatin and ATRA is superior to cisplatin alone in suppressing bladder tumor 
growth in vivo. A. Tumor volumes in TCCSUP tumor-bearing mice receiving cisplatin or ATRA alone. TCCSUP cells (2 × 106) were 
subcutaneously inoculated into NOD/SCID mice. When tumor volumes reached 100 mm3, the mice were treated with cisplatin (4 mg/kg), 
ATRA (10 mg/kg), saline, or the solvent alone. B. Immunohistochemical staining for Oct4 in the tumors excised at day 30 from the mice 
described in A (×400 magnification, scale bar, 50 μm). Negative control slides stained with isotype control mouse IgG were included. C. 
Tumor volumes in TCCSUP tumor-bearing mice receiving cisplatin alone or in combination with ATRA. Tumor-bearing mice as described 
in A were treated with cisplatin (4 mg/kg) with or without ATRA (10 mg/kg). D. Immunohistochemical staining for Oct4 in the tumors 
excised at day 34 from the mice described in C (×400 magnification, scale bar, 50 μm). Negative control slides stained with isotype control 
mouse IgG were included.
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Our data can explain, in part, the high recurrence rate 
and drug resistance of bladder cancer from neoadjuvant 
chemotherapy. However, large-scale studies on the 
comparison between neoadjuvant and postoperative 
chemotherapy should be conducted for further evaluation.
The multidrug resistant (MDR) phenotype has 
been widely recognized in chemotherapy for bladder 
cancer [35]. The ATP-binding cassette (ABC) transporter 
family of transmembrane proteins have been linked to 
resistance of doxorubicin, paclitaxel, methotrexate, and 
mitomycin C by promoting drug efflux in various cancer 
types [36]. For cisplatin resistance, limited intracellular 
accumulation of cisplatin most often derives from reduced 
uptake, rather than increased efflux [37]. Mitomycin C, 
a DNA cross-linking agent, is unique as an anticancer 
drug in that it is preferentially converted to an active form 
through enzymatic reduction in hypoxic regions of solid 
tumors [38]. It is thus more toxic to hypoxic cells than 
to aerobic cells [39, 40]. Regarding antimetabolites 5-FU, 
gemcitabine, and methotrexate used in the present study, 
increased expression of thymidylate synthase, which is the 
target of 5-FU, was shown to be a resistance mechanism 
to 5-FU [41]. Dysregulation of the enzymes participating 
in the gemcitabine metabolic pathway is one of the 
mechanisms responsible for gemcitabine resistance [42]. 
Amplification of the dihydrofolate reductase (DHFR) gene 
resulting in increased levels of the enzyme was identified 
as one mechanism of acquired methotrexate resistance 
[43]. Given the complexity and heterogeneity of bladder 
cancer as well as the variety of mechanisms involved in 
drug resistance, further studies are warranted to uncover 
the molecular basis by which Oct4 induces acquired 
resistance of bladder cancer to different anticancer drugs.
In the management of cancer patients, drug 
resistance is a major cause of treatment failure. Our results 
indicate that suppression of Oct4 expression may improve 
drug susceptibility to overcome the acquired resistance to 
chemotherapeutic drugs. ATRA, a derivative of vitamin 
A, can promote ES cell differentiation by repressing Oct4 
gene expression through several retinoic acid-responsive 
elements (RAREs) located in the promoter-enhancer 
region of the Oct4 gene [21]. We have previously shown 
that inhibition of Oct4 expression by ATRA in bladder 
cancer cells renders cells less susceptible to cytolytic 
effects induced by an oncolytic adenovirus carrying the 
Oct4 response element (ORE) [44]. In the present study, we 
demonstrate that inhibition of Oct4 expression by ATRA 
improves the sensitivity of cancer cells to cisplatin. ATRA 
is used as an anticancer agent for acute promyelocytic 
leukemia [45]. The combined treatment with ketoconazole 
and ATRA for bladder cancer after transurethral resection 
of bladder tumor (TURBT) significantly improved the 
survival and reduced recurrence through decreasing 
levels of vascular endothelial growth factor (VEGF) and 
transforming growth factor-α (TGF-β) [46]. In addition, 
when compared with methotrexate, vinblastine, and 
doxorubicin plus cisplatin, combination treatment with 
gemcitabine plus cisplatin offered a similar survival 
result but with a better safety profile and tolerability in 
patients with bladder cancer [47, 48]. In the present study, 
we demonstrate the synergistic cytotoxicity of ATRA 
combined with cisplatin, suggesting that inhibition of Oct4 
may be a potentially effective therapeutic strategy against 
cancer and provide an additional benefit for chemotherapy 
and/or radiotherapy.
ATRA exerts pleiotropic effects on cell proliferation 
and differentiation, which can be independent of its 
effect on Oct4 gene expression [45]. It can promote the 
differentiation of dendritic cells in cancer patients [49]. It 
has also been suggested to modulate the MAPK pathway 
[50] and repress invasion and stem cell phenotypes by 
induction of metastasis suppressors through RAREs 
[51]. Therefore, ATRA provides multiple advantages for 
cancer therapy because it induces differentiation of CSC-
like cells, rendering them sensitive to chemotherapy. 
ATRA-mediated Oct4 inhibition may not only suppress 
the promoter activity of Oct4, but also be through the 
degradation of Pin1, a peptidyl-prolyl isomerase. Pin1 
is induced upon cellular reprogramming and enhances 
generation of induced pluripotent stem (iPS) cells 
[52]. Pin1 interacts with the phosphorylated Ser12-Pro 
motif of Oct4, which in turn facilitates the stability and 
transcriptional activity functions of Oct4. Thus, ATRA 
simultaneously blocks multiple Pin1-regulated cancer-
driving pathways, an attractive property for treating 
aggressive and drug-resistant tumors [53].
In the present study, we have provided evidence that 
Oct4 expression is enhanced in bladder cancer cells after 
treatment with various chemotherapeutic agents, rendering 
bladder cancer chemoresistant. In a broad sense, as Oct4 is 
expressed in a variety of cancers, chemotherapy-induced 
Oct4 expression and the resultant drug resistance may also 
operate in different cancers. A growing body of evidence 
has shown multifunctional oncogenic transcription factors 
as potential targets for cancer therapy. Since cisplatin-
based chemotherapy is common for cancer therapy, 
suppression of Oct4 expression by the pharmacological 
inhibitor ATRA or RNA interference-mediated silencing 
may provide a promising strategy for treating different 
cancers. This notion is clearly demonstrated in our 
results by the synergistic antitumor effects of combined 
treatment of cisplatin and ATRA on mice bearing Oct4-
overexpressing human bladder tumor xenografts. 
Furthermore, our findings also reinforce the importance of 
precautions on preventing drug resistance via Oct4 when 
neoadjuvant chemotherapy is considered. Although we 
show that Oct4 induces acquired resistance of cancer cells 
to chemotherapeutic agents, the exact mechanisms of how 
anticancer drugs enhance Oct4 expression to confer drug 




This study analyzed 122 specimens of 110 
consecutive patients with high-grade, stages T1-2 
urothelial carcinoma of urinary bladder treated with 
TURBT between 2006 and 2010 at National Cheng Kung 
University (NCKU) Hospital. After TURBT, these patients 
received intravesical chemotherapy with epirubicin. 
None of the patients received neoadjuvant chemotherapy 
or preoperative radiotherapy. There was no metastatic 
disease at the time of surgery. This study was approved 
by Institutional Review Board of NCKU Hospital, and 
informed consent was obtained from each patient. Tumor 
recurrence was determined from hospital records.
Cell culture and mice
Human bladder cancer cell lines (TCCSUP, 
J82, TSGH-8301, and T24) and human immortalized 
uroepithelial cell line (SV-HUC-1) have been 
previously described [44]. Cells were cultured in 
complete medium consisting of Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% 
cosmic calf serum (Hyclone), 2 mmol/L L-glutamine, 
and 50 μg/mL gentamicin. Stable Oct4-overexpressing 
or Oct4-knockdown cells were established using 
lentiviral vectors and puromycin selection as described 
previously [54, 55]. Cisplatin-resistant TCCSUP cells 
were obtained by culturing cells in complete medium 
containing cisplatin (1 μg/ml) as previously described. 
Male 6-8-week-old NOD/SCID mice were obtained 
from the Laboratory Animal Center of NCKU. All 
animal experiments were conducted following the 
guidelines approved by the Laboratory Animal Care and 
Use Committee of NCKU.
Plasmids and lentiviral vectors
The lentiviral vector encoding human Oct4 was 
purchased from Addgene (pSin-EF2-Oct4-Pur, Addgene 
plasmid 16579). To construct the control lentiviral 
vector pSin-null, pSin-EF2-Oct4-Pur was digested 
with SpeI and BamHI to excise the Oct4 cDNA, and 
the resulting large fragment was filled-in with T4 DNA 
polymerase (Takara) and subsequently self-ligated by T4 
DNA ligase (Invitrogen). For knockdown experiments, 
pLKO.1-puro-based lentiviral vectors, including 
stem-loop cassettes encoding shRNA for human Oct4 
(TRCN0000004882 and TRCN0000004883, designated 
shOct4 TRCN4882 and shOct4 TRCN4883) and 
luciferase (TRCN 0000072246, designated shLuc), 
were obtained from the National RNAi Core Facility, 
Academia Sinica, Taiwan. Lentiviruses were produced 
and titrated as previously described [55].
Quantitative real-time RT-PCR analysis
Total RNA (2 μg) was reverse-transcribed into 
cDNA using the Verso™ cDNA synthesis kit (Thermo 
Fisher Scientific). Quantitative real-time RT-PCR was 
performed using a SmartCycler System (Cephid). 
Each reaction contained 50 ng cDNA, SYBR Premix 
Ex Taq (TaKaRa), and 5 μmol of each forward and 
reverse primer. The following primers were used: 
human Oct4, 5’-GTCCGAGTGTGGTTCTGTA-3’ 
(forward) and 5’-CTCAGTTTGAATGCATGGGA-3’ 
(reverse); human MDR1, 5’-CCAGGCTTGCTGTA
ATTACCCAGAAT-3’ (forward) and 5’-TTGGCAT
AGTCAGGAGCAAATGAACT-3’ (reverse); human 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
5’-ACTTCAACAGCGACACCCACT-3’ (forward) and 
5’-GCCAAATTCGTTGTCATACCAG-3’ (reverse). 
Normalization was performed using GAPDH as the 
internal control, and relative gene expression was 
calculated using the comparative 2(-∆∆Ct) method [56].
Immunohistochemistry, immunoblotting, and 
immunofluorescence
For immunohistochemistry, specificity of the anti-
Oct4 antibody used in this study has been validated in 
our previous papers showing immunoreactivity with 
bladder cancer cells and ES cells, but not with normal 
cells [14, 44]. Immunohistochemistry was performed 
on serial formalin-fixed, paraffin-embedded sections of 
human and mouse bladder tissue after antigen retrieval 
with proteinase K. After blocking with 5% BSA, tissue 
sections were incubated with mouse anti-Oct4 monoclonal 
antibody (Santa Cruz, sc-5279) at 4°C overnight, 
followed by incubation with horseradish peroxidase 
(HRP)-conjugated goat anti-mouse IgG (H+L) (Jackson 
Laboratory, 115-035-003) at room temperature for 2 h. The 
reactivity was visualized with aminoethyl carbazole (red 
color, Invitrogen) and counterstained with hematoxylin. 
Immunoblot analysis was performed to detect Oct4, 
RARα, and β-actin (as the loading control) using rabbit 
anti-Oct4 antibody (Cell Signaling, #2750), goat anti-
RARα (Abcam, ab28767), and anti-β-actin-peroxidase 
antibody (Sigma-Aldrich, A3854), respectively, as 
previously described [57]. For immunofluorescence 
staining, cancer cells were fixed in 4% paraformaldehyde 
for 15 min, treated with 0.1% Triton X-100 in PBS for 
5 min at room temperature, and then blocked with 1% 
bovine serum albumin. Sections of formalin-fixed, 
paraffin-embedded human and mouse bladder tissue 
were also subjected to immunofluorescence staining, 
as previously described [58]. Cells and tumor tissue 
sections were then incubated with anti-CD44-PE antibody 
(Miltenyi Biotec, 130-098-108) and mouse anti-Oct4 
monoclonal (Santa Cruz, sc-5279) at 4°C overnight. After 
being washed with PBS, they were sequentially incubated 
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with Alexa Fluor488-goat anti-mouse IgG (H+L) (Life 
Technologies, A-11001) for 2 h at room temperature. The 
nucleus was counterstained with DAPI (50 μg/ml).
Drug sensitivity assay and drug ion analysis
Various bladder cancer cells (2 × 103) that were 
cultured in 96-well plates in complete medium overnight 
were refed with fresh medium containing various 
concentrations of chemotherapeutic drugs and cultured for 
72 h. A colorimetric WST-8 assay (Dojindo Laboratories) 
was used to determine cell viability. The IC50 values were 
determined as the drug concentration at 50% inhibition of 
cell growth.
To analyze the effect of the drug combination, 
TCCSUP cells (4 × 103) cultured in 96-well plates were 
treated with cisplatin ranging from 0 to 10 μg/ml plus 
ATRA (0.1 μM) or the solvent for 72 h. The cytotoxic 
effect was assessed by the WST-8 assay. The CDI was 
used to analyze drug combinations as previously described 
[22–24]. The CDI was calculated by the following 
formula: CDI = AB/(A × B). AB is the survival rate of the 
two-drug combination group relative to the control group, 
and A or B is the survival rate of the single drug group 
relative to the control group. The CDI values of < 1, = 1, 
and > 1 indicate that the drugs are synergistic, additive, 
and antagonistic, respectively.
Animal experiments
NOD/SCID mice were inoculated subcutaneously 
with parental or cisplatin-resistant TCCSUP cells (1 × 107) 
at day 0, followed by intraperitoneal injection of cisplatin 
(4 mg/kg) at days 5, 7, 9, 11, and 13. In addition, Oct4-
overexpressing and control TCCSUP cells were employed 
for in vivo experiments. TCCSUP cells (2 × 106) that had 
been transduced with lentiviral vectors encoding Oct4 or 
with control vectors were inoculated subcutaneously into 
the right flank of NOD/SCID mice at day 0. Subsequently, 
the mice were treated intraperitoneally with cisplatin (4 
mg/kg) or saline when their tumor volumes reached 100 
mm3. In other sets of the experiment, TCCSUP tumor-
bearing NOD/SCID mice were treated intraperitoneally 
with cisplatin (4 mg/kg), ATRA (10 mg/kg), saline, or 
the vehicle (solvent) alone. Furthermore, the tumor-
bearing mice were treated with cisplatin, cisplatin plus 
ATRA, cisplatin plus solvent, or saline. All of the mice 
were monitored for tumor growth. Tumor volumes were 
calculated as: length × width2 × 0.45.
Statistical analysis
Recurrence-free curves were calculated by the 
Kaplan and Meier method and compared by the log-rank 
test. Differences in the expression levels of Oct4 between 
primary and recurrent tumor tissue were evaluated with 
the Mann-Whitney U test. Differences in tumor volume 
and cell viability between groups were compared by 
two-way analysis of variance (ANOVA) with repeated 
measures. The remaining data were analyzed by one-way 
ANOVA with Bonferroni post hoc test. The differences 
were considered significant if P values were < 0.05.
ACKNOWLEDGMENTS
The RNAi reagents were obtained from the National 
RNAi Core Facility located at the Institute of Molecular 
Biology/Genomic Research Center, Academia Sinica, 
Taiwan.
CONFLICTS OF INTEREST
The authors do not have any conflicts of interest to 
report.
FINANCIAL SUPPORT
This work was supported by the National Science 
Council, Taiwan (NSC 98-2628-B-006-014-MY3).
REFERENCES
1. Wang D, Lippard SJ. Cellular processing of platinum 
anticancer drugs. Nat Rev Drug Discov. 2005; 4:307-320.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, 
cancer, and cancer stem cells. Nature. 2001; 414:105-111.
3. Medema JP. Cancer stem cells: the challenges ahead. Nat 
Cell Biol. 2013; 15:338-344.
4. Cain JW, Hauptschein RS, Stewart JK, Bagci T, Sahagian 
GG, Jay DG. Identification of CD44 as a surface biomarker 
for drug resistance by surface proteome signature 
technology. Mol Cancer Res. 2011; 9:637-647.
5. Liu J, Xiao Z, Wong SK, Tin VP, Ho KY, Wang J, Sham 
MH, Wong MP. Lung cancer tumorigenicity and drug 
resistance are maintained through ALDH(hi)CD44(hi) 
tumor initiating cells. Oncotarget. 2013; 4:1698-1711.
6. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, 
Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz 
E, Caserini R, Lo Vullo S, et al. Highly tumorigenic lung 
cancer CD133+ cells display stem-like features and are 
spared by cisplatin treatment. Proc Natl Acad Sci USA. 
2009; 106:16281-16286.
7. Jung M, Peterson H, Chavez L, Kahlem P, Lehrach H, Vilo 
J, Adjaye J. A data integration approach to mapping OCT4 
gene regulatory networks operative in embryonic stem cells 
and embryonal carcinoma cells. PLoS One. 2010; 5:e10709.
8. Pan GJ, Chang ZY, Schöler HR, Pei D. Stem cell 
pluripotency and transcription factor Oct4. Cell Res. 2002; 
12:321-329.
9. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang 
CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, 
Oncotarget14www.impactjournals.com/oncotarget
Chiou SH. Oct-4 expression maintained cancer stem-like 
properties in lung cancer-derived CD133-positive cells. 
PLoS One. 2008; 3:e2637.
10. Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe 
AD, Fink LM, Ma Y, Wong MP. Non-small cell lung 
cancer cells expressing CD44 are enriched for stem cell-
like properties. PLoS One. 2010; 5:e14062.
11. Achuthan S, Santhoshkumar TR, Prabhakar J, Nair 
SA, Pillai MR. Drug-induced senescence generates 
chemoresistant stemlike cells with low reactive oxygen 
species. J Biol Chem. 2011; 286:37813-37829.
12. She JJ, Zhang PG, Wang ZM, Gan WM, Che XM. 
Identification of side population cells from bladder cancer 
cells by DyeCycle Violet staining. Cancer Biol Ther. 2008; 
7:1663-1668.
13. Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like 
side-population cells are tumourigenic and chemoresistant. 
Br J Cancer. 2010; 102:1276-1283.
14. Chang CC, Shieh GS, Wu P, Lin CC, Shiau AL, Wu CL. 
Oct-3/4 expression reflects tumor progression and regulates 
motility of bladder cancer cells. Cancer Res. 2008; 
68:6281-6291.
15. Lu CS, Hsieh JL, Lin CY, Tsai HW, Su BH, Shieh GS, 
Su YC, Lee CH, Chang MY, Wu CL, Shiau AL. Potent 
antitumor activity of Oct4 and hypoxia dual-regulated 
oncolytic adenovirus against bladder cancer. Gene Ther. 
2015; 22:305-315.
16. Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, Chen 
KK, Lopez JP, Poon RT, Fan ST. Octamer 4 (Oct4) 
mediates chemotherapeutic drug resistance in liver cancer 
cells through a potential Oct4-AKT-ATP-binding cassette 
G2 pathway. Hepatology. 2010; 52:528-539.
17. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA 
Cancer J Clin. 2016; 66:7-30.
18. Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng 
KK, Wallace DM, et al. Mechanisms of recurrence of Ta/T1 
bladder cancer. Ann R Coll Surg Engl. 2010; 92:519-524.
19. Holohan C, Van Schaeybroeck S, Longley DB, Johnston 
PG. Cancer drug resistance: an evolving paradigm. Nat Rev 
Cancer. 2013; 13:714-726.
20. Huang P, Chen J, Wang L, Na Y, Kaku H, Ueki H, Sasaki 
K, Yamaguchi K, Zhang K, Saika T, Nasu Y, Watanabe M, 
Kumon H. Implications of transcriptional factor, OCT-4, 
in human bladder malignancy and tumor recurrence. Med 
Oncol. 2012; 29:829-834.
21. Pikarsky E, Sharir H, Ben-Shushan E, Bergman Y. Retinoic 
acid represses Oct-3/4 gene expression through several 
retinoic acid-responsive elements located in the promoter-
enhancer region. Mol Cell Biol. 1994; 14:1026-1038.
22. Cao SS, Zhen YS. Potentiation of antimetabolite antitumor 
activity in vivo by dipyridamole and amphotericin B. 
Cancer Chemother Pharmacol. 1989; 24:181-186.
23. Xu SP, Sun GP, Shen YX, Peng WR, Wang H, Wei W. 
Synergistic effect of combining paeonol and cisplatin on 
apoptotic induction of human hepatoma cell lines. Acta 
Pharmacol Sin. 2007; 28:869-878.
24. Wang D, Wang Z, Tian B, Li X, Li S, Tian Y. Two hour 
exposure to sodium butyrate sensitizes bladder cancer to 
anticancer drugs. Int J Urol. 2008; 15:435-441.
25. Yan Y, Zuo X, Wei D. Concise Review: Emerging Role 
of CD44 in Cancer Stem Cells: A Promising Biomarker 
and Therapeutic Target. Stem Cells Transl Med. 2015; 
4:1033-1043.
26. Chen K, Huang YH, Chen JL. Understanding and targeting 
cancer stem cells: therapeutic implications and challenges. 
Acta Pharmacol Sin. 2013; 34:732-740.
27. Clevers H. The cancer stem cell: premises, promises and 
challenges. Nat Med. 2011; 17:313-319.
28. Visvader JE, Lindeman GJ. Cancer stem cells in solid 
tumours: accumulating evidence and unresolved questions. 
Nat Rev Cancer. 2008; 8:755-768.
29. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty 
PA, Guerra M, Guo W, Xu X. Acquired cancer stem cell 
phenotypes through Oct4-mediated dedifferentiation. 
Oncogene. 2012; 31:4898-4911.
30. Li C, Yan Y, Ji W, Bao L, Qian H, Chen L, Wu M, Chen H, 
Li Z, Su C. OCT4 positively regulates Survivin expression 
to promote cancer cell proliferation and leads to poor 
prognosis in esophageal squamous cell carcinoma. PLoS 
One. 2012; 7:e49693.
31. Guo Y, Mantel C, Hromas RA, Broxmeyer HE. Oct-4 is 
critical for survival/antiapoptosis of murine embryonic 
stem cells subjected to stress: effects associated with Stat3/
survivin. Stem Cells. 2008; 26:30-34.
32. Freitas DP, Teixeira CA, Santos-Silva F, Vasconcelos MH, 
Almeida GM. Therapy-induced enrichment of putative lung 
cancer stem-like cells. Int J Cancer. 2014; 134:1270-1278.
33. Zhao H, Jin S, Fan F, Fan W, Tong T, Zhan Q. Activation of 
the transcription factor Oct-1 in response to DNA damage. 
Cancer Res. 2000; 60:6276-6280.
34. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin 
resistance: a cellular self-defense mechanism resulting from 
multiple epigenetic and genetic changes. Pharmacol Rev. 
2012; 64:706-721.
35. Naito S, Yokomizo A, Koga H. Mechanisms of drug 
resistance in chemotherapy for urogenital carcinoma. Int J 
Urol. 1999; 6:427-439.
36. Thomas H, Coley HM. Overcoming multidrug resistance 
in cancer: an update on the clinical strategy of inhibiting 
p-glycoprotein. Cancer Control. 2003; 10:159-165.
37. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, 
Kepp O, Castedo M, Kroemer G. Molecular mechanisms of 
cisplatin resistance. Oncogene. 2012; 31:1869-1883.
38. Cummings J. The role of reductive enzymes in cancer 
cell resistance to mitomycin C. Drug Resist Updat. 2000; 
3:143-148.
39. Teicher BA, Lazo JS, Sartorelli AC. Classification of 
antineoplastic agents by their selective toxicities toward 
Oncotarget15www.impactjournals.com/oncotarget
oxygenated and hypoxic tumor cells. Cancer Res. 1981; 
41:73-81.
40. Rauth AM, Mohindra JK, Tannock IF. Activity of 
mitomycin C for aerobic and hypoxic cells in vitro and in 
vivo. Cancer Res. 1983; 43:4154-4158.
41. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, 
Allegra CJ, Danenberg PV, Leichman L. Thymidylate 
synthase gene and protein expression correlate and are 
associated with response to 5-fluorouracil in human 
colorectal and gastric tumors. Cancer Res. 1995; 
55:1407-1412.
42. Jia Y, Xie J. Promising molecular mechanisms responsible 
for gemcitabine resistance in cancer. Genes Dis. 2015; 
2:299-306.
43. Schweitzer BI, Dicker AP, Bertino JR. Dihydrofolate 
reductase as a therapeutic target. FASEB J. 1990; 
4:2441-2452.
44. Wu CL, Shieh GS, Chang CC, Yo YT, Su CH, Chang MY, 
Huang YH, Wu P, Shiau AL. Tumor-selective replication of 
an oncolytic adenovirus carrying Oct-3/4 response elements 
in murine metastatic bladder cancer models. Clin Cancer 
Res. 2008; 14:1228-1238.
45. Schenk T, Stengel S, Zelent A. Unlocking the potential 
of retinoic acid in anticancer therapy. Br J Cancer. 2014; 
111:2039-2045.
46. Hameed DA, el-Metwally TH. The effectiveness of retinoic 
acid treatment in bladder cancer: impact on recurrence, 
survival and TGFalpha and VEGF as end-point biomarkers. 
Cancer Biol Ther. 2008; 7:92-100.
47. von der Maase H, Hansen SW, Roberts JT, Dogliotti 
L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, 
Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, 
et al. Gemcitabine and cisplatin versus methotrexate, 
vinblastine, doxorubicin, and cisplatin in advanced or 
metastatic bladder cancer: results of a large, randomized, 
multinational, multicenter, phase III study. J Clin Oncol. 
2000; 18:3068-3077.
48. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti 
L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-
term survival results of a randomized trial comparing 
gemcitabine plus cisplatin, with methotrexate, vinblastine, 
doxorubicin, plus cisplatin in patients with bladder cancer. 
J Clin Oncol. 2005; 23:4602-4608.
49. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, 
Kübler H, Yancey D, Dahm P, Vieweg J. Reversal of 
myeloid cell-mediated immunosuppression in patients with 
metastatic renal cell carcinoma. Clin Cancer Res. 2008; 
14:8270-8278.
50. Karsy M, Albert L, Tobias ME, Murali R, Jhanwar-Uniyal 
M. All-trans retinoic acid modulates cancer stem cells of 
glioblastoma multiforme in an MAPK-dependent manner. 
Anticancer Res. 2010; 30:4915-4920.
51. Oldridge EE, Walker HF, Stower MJ, Simms MS, Mann 
VM, Collins AT, Pellacani D, Maitland NJ. Retinoic acid 
represses invasion and stem cell phenotype by induction 
of the metastasis suppressors RARRES1 and LXN. 
Oncogenesis. 2013; 2:e45.
52. Nishi M, Akutsu H, Masui S, Kondo A, Nagashima Y, 
Kimura H, Perrem K, Shigeri Y, Toyoda M, Okayama A, 
Hirano H, Umezawa A, Yamamoto N, et al. A distinct role 
for Pin1 in the induction and maintenance of pluripotency. 
J Biol Chem. 2011; 286:11593-11603.
53. Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio 
J, Luo M, You MH, Yao Y, Kondo A, Hu H, Bozkurt G, 
Moerke NJ, et al. Active Pin1 is a key target of all-trans 
retinoic acid in acute promyelocytic leukemia and breast 
cancer. Nat Med. 2015; 21:457-466.
54. Wang CR, Shiau AL, Chen SY, Cheng ZS, Li YT, Lee CH, 
Yo YT, Lo CW, Lin YS, Juan HY, Chen YL, Wu CL. Intra-
articular lentivirus-mediated delivery of galectin-3 shRNA 
and galectin-1 gene ameliorates collagen-induced arthritis. 
Gene Ther. 2010; 17:1225-1233.
55. Salmon P, Trono D. Production and titration of 
lentiviral vectors. Curr Protoc Hum Genet. 2007; 
54:12.10.1–12.10.24.
56. Schmittgen TD, Livak KJ. Analyzing real-time PCR 
data by the comparative C(T) method. Nat Protoc. 2008; 
3:1101-1108.
57. Su BH, Tseng YL, Shieh GS, Chen YC, Shiang YC, 
Wu P, Li KJ, Yen TH, Shiau AL, Wu CL. Prothymosin 
α overexpression contributes to the development of 
pulmonary emphysema. Nat Commun. 2013; 4:1906.
58. Hsieh JL, Lu CS, Huang CL, Shieh GS, Su BH, Su YC, 
Lee CH, Chang MY, Wu CL, Shiau AL. Acquisition of 
an enhanced aggressive phenotype in human lung cancer 
cells selected by suboptimal doses of cisplatin following 
cell deattachment and reattachment. Cancer Lett. 2012; 
321:36-44.
